(Press-News.org) One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons, according to a study published in JAMA today by the IVY Network research group.
RSV causes substantial seasonal illness during fall and winter in the U.S., with an estimated 100,000-150,000 hospitalizations and 4,000-8,000 deaths occurring annually among adults 60 or older.
The results reinforce the recommendations for RSV vaccines in older adults and lay the groundwork for understanding how long a single dose of the vaccine may be effective, according to Wesley Self, MD, MPH, principal investigator for the IVY Network and Senior Vice President for Clinical Research at Vanderbilt University Medical Center.
“These results clearly demonstrate that the RSV vaccines prevent hospitalizations and critical illness due to RSV infection among older Americans,” Self said. “It is exciting to see the public health benefits of this new vaccination program.”
Investigators used data from a multicenter hospital network known as the IVY Network (The Investigating Respiratory Viruses in the Acutely Ill Network) to assess RSV vaccine effectiveness. They used a test-negative, case-control study design among 6,958 persons 60 years or older who had been hospitalized with acute respiratory illness at one of 26 hospitals in 20 US states during two RSV seasons from October 1, 2023–March 31, 2024 and October 1, 2024–April 30, 2025.
Overall, vaccination reduced the risk of RSV hospitalization by 58% during two RSV seasons, including 69% in the first year after vaccination and 48% in the second year after vaccination.
“Our data show that the beneficial effects of RSV vaccines appear to wane over time,” Self said. “Redosing the vaccine at some interval after the initial dose could be a strategy to maintain protection over longer periods of time. It will be important to continue to closely monitor vaccine effectiveness over time to understand how long the benefit lasts after a single dose and if repeat dosing should be considered.”
Current RSV vaccine recommendations are for all adults aged 75 years and older and those aged 60-74 years who are at an increased risk of severe RSV.
This study was funded by the U.S. Centers for Disease Control and Prevention (CDC) via award 75D30122C14944.
END
One shot of RSV vaccine effective against hospitalization in older adults for two seasons
2025-08-30
ELSE PRESS RELEASES FROM THIS DATE:
Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults
2025-08-30
About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant.
Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s ...
Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis
2025-08-30
About The Study: In this study, clonal hematopoiesis of indeterminate potential (CHIP) was a strong risk factor for myocarditis and pericarditis among middle-aged adults. Targeting CHIP and its downstream pathways may represent a strategy for preventing or treating pericarditis and myocarditis.
Corresponding Author: To contact the corresponding author, Michael C. Honigberg, MD, MPP, email mhonigberg@mgh.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions ...
Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine
2025-08-30
About The Study: In this prespecified analysis of the DANFLU-2 trial, the risk of incident myocarditis or pericarditis was lower among individuals randomized to high-dose inactivated influenza vaccine vs standard-dose- inactivated influenza vaccine. Despite sporadic reports of myocarditis and pericarditis associated with influenza vaccination, the consistency of our results with vs without inclusion of events occurring immediately after vaccination negates a dose-response association and a causal link.
Corresponding Author: To ...
High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults
2025-08-30
About The Study: This study found reduced incidence of cardiorespiratory hospitalization among those who received high-dose inactivated influenza vaccine vs standard-dose inactivated influenza vaccine, driven by a lower incidence of cardiovascular hospitalizations, and particularly heart failure hospitalizations. These differences should be interpreted as exploratory findings in the setting of a large randomized clinical trial with a neutral primary outcome.
Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, ...
Prevalence, determinants, and time trends of cardiovascular health in the WHO African region
2025-08-30
About The Study: This situational analysis of cross-sectional WHO STEPS surveys of cardiovascular health (CVH) status region identified actionable factors of the CVH status across 22 countries in the WHO African Region. This information is crucial for guiding policy efforts in cardiovascular disease prevention in countries of the WHO African Region.
Corresponding Author: To contact the corresponding author, Jean-Philippe Empana, MD, PhD, email jean-philippe.empana@inserm.fr.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including ...
New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers
2025-08-30
A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices.
REBOOT, presented in a Hotline session of the ESC congress in Madrid, ...
CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients
2025-08-30
Madrid, August 30, 2025. An international clinical trial coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with the Mario Negri Institute for Pharmacological Research in Milan, has found that beta-blockers—drugs commonly prescribed for a range of cardiac conditions—offer no clinical benefit for patients who have had an uncomplicated myocardial infarction (i.e., without deterioration of the heart function after the event).
The findings—published in two articles in The New England Journal of Medicine and The Lancet and presented today during a “Hot Line” ...
Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock
2025-08-30
About The Study: Randomization systolic blood pressure (SBP) was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating.
Corresponding Author: To contact the corresponding author, Astrid Duus Mikkelsen, MD, email astrid.duus.mikkelsen@reigonh.dk.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including ...
Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes
2025-08-30
Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function. Beta blockers have been the standard treatment for these patients for 40 years.
This is a breakthrough discovery from the “REBOOT Trial” with senior investigator Valentin Fuster, MD, PhD, President of Mount Sinai Fuster Heart Hospital and General Director of Spain’s Centro Nacional de Investigaciones Cardiovasculares ...
High Mountain Asia’s shrinking glaciers linked to monsoon changes
2025-08-29
Glaciers across High Mountain Asia are losing more than 22 gigatons of ice per year—the equivalent to nearly 9 million Olympic swimming pools, according to research from the University of Utah and Virginia Tech. The impact of a warming climate on glacial loss is undisputed—this new study provides the first evidence that seasonal shifts in rainfall and snowfall patterns, particularly of the South Asian monsoons, are also exacerbating glacier melting across the region.
“These findings highlight that glaciers dominated by the South Asian monsoons, such as the Central Himalaya, ...